Saturday, 17 October 2026European Markets

FERMENTALG Stock Went Down By Over 11% So Far Today

Loading stream...

(vianews) - shares of fermentalg (cac 40: falg.pa) dropped by a staggering 11.35% to €0.66 at 11:52 est on thursday, after two sequential sessions in a row of gains. cac 40 is rising 0.42% to €7,357.83, after two successive sessions in a row of gains. this seems, at the moment, a somewhat bullish trend trading session today.

about fermentalg

fermentalg sa develops, produces, and sells active ingredients extracted from microalgae for the food, health, nutrition, and environment sectors in france and internationally. it offers dha origins, a plant-based dha oil; aquafeeds and pet foods; blue origin, a natural color; and environmental and clean air solutions that captures co2 in industries. the company was incorporated in 2009 and is headquartered in libourne, france.

earnings per share

as for profitability, fermentalg has a trailing twelve months eps of €-0.24.

volume

today's last reported volume for fermentalg is 331434 which is 480.39% above its average volume of 57105.

more news about fermentalg (falg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com